News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene International Sárl (CELG) Release: Study Evaluating REVLIMID® Combination Compared to Autologous Stem Cell Transplant with or without REVLIMID Maintenance in Newly-Diagnosed Multiple Myeloma Presented at American Society of Clinical Oncology


6/3/2013 7:59:00 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced data from a study comparing melphalan, prednisone and REVLIMID (lenalidomide) (MPR) with high-dose chemotherapy and tandem autologous stem cell transplant (MEL200), as well as evaluating the effect of lenalidomide maintenance in patients with newly-diagnosed multiple myeloma were presented during a June 3rd oral session at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting in Chicago, Ill.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES